Radiotherapy Receipt and Omission After Oncoplastic Breast-Conserving Surgery: Study Design and Methods

Overview

The study was designed to assess whether omission of adjuvant radiotherapy is associated with postoperative complications and patient-reported outcomes after oncoplastic breast-conserving surgery (OPBCS). The supplied article excerpt describes the rationale and retrospective cohort methods but does not provide study results, so comparative outcomes cannot be reported.

Background

Breast-conserving surgery is an established treatment for early-stage breast cancer. Oncoplastic breast-conserving surgery (OPBCS) combines tumor removal with volume-displacement or volume-replacement techniques to address contour and volume changes. The source describes adjuvant radiotherapy (RT) as conventional after breast-conserving surgery to reduce locoregional recurrence risk and notes potential tissue effects, including microvascular injury, fibrosis, fat necrosis, skin contracture, and breast-volume loss. It also cites LUMINA and IDEA as prospective studies of RT omission in carefully selected patients with favorable tumor biology or low genomic risk. The study assessed the association between RT omission and postoperative complications and patient-reported outcomes after OPBCS.

Data Highlights

The provided excerpt reports the study design and eligibility period but contains no numerical outcome results.

Key Findings

• The study retrospectively evaluated adult women who underwent OPBCS within one healthcare network from 2017 through 2024.
• Eligible procedures included lumpectomy followed by immediate or delayed oncoplastic reconstruction using volume displacement or volume replacement techniques.
• Patients were categorized by receipt of adjuvant radiotherapy; patients refusing radiotherapy were included in the omission group.
• The stated study objective was to assess the association of radiotherapy omission with postoperative complications and patient-reported outcomes after OPBCS.
• The article introduction describes radiotherapy-related tissue changes, including microvascular injury, fibrosis, fat necrosis, skin contracture, and breast-volume loss.
• The supplied excerpt does not report cohort size, comparative outcome data, or study conclusions; the related article listings provide titles and citations but no findings relevant to this cohort.

Clinical Implications

The supplied excerpt describes the study rationale and methods but does not report comparative results. It therefore does not establish whether RT omission was associated with differences in complications or patient-reported outcomes.

Conclusion

The supplied material describes a retrospective study evaluating RT receipt or omission after OPBCS, including postoperative complications and patient-reported outcomes. Because results are not included, no comparative outcome conclusion can be drawn.

Related Resources & Content

1. A. Toledano et al., ASCO Publications, 2006 — Impact on the cosmetic outcome of concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery: Differences between patient’s and doctor’s views
2. Maho Tanaka et al., ASCO Publications, 2021 — Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Escalation or De-Escalation?
3. ASTRO, PubMed, 2024 — Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline
4. ESMO, Annals of Oncology, 2024 — Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5. UK IMPORT LOW investigators, The Lancet Oncology, 2025 — Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
6. PMC, 2023 — Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer
7. PMC, 2020 — Consensus statement on tumour bed localization for radiation after oncoplastic breast surgery
8. ASCO Publications — Impact on the cosmetic outcome of concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery: Differences between patient’s and doctor’s views
9. ASCO Publications — New aspects regarding the cosmetic outcome after neoadjuvant radiochemotherapy in breast cancer patients.
10. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline
11. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
12. Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes
13. Consensus statement on tumour bed localization for radiation after oncoplastic breast surgery
14. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology
15. Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial - The Lancet Oncology
16. Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer - PMC
17. Consensus statement on tumour bed localization for radiation after oncoplastic breast surgery - PMC